J&J's Imaavy becomes first approved therapy for rare anemia
Johnson & Johnson's monoclonal antibody Imaavy has received an expanded FDA approval, making it the first treatment specifically for warm autoimmune hemolytic anemia. The condition causes severe anemia and fatigue due to autoantibodies. Additionally, the drug secured two approvals in Japan, though specifics were not disclosed.
Related stories
Regeneron wins FDA approval for first treatment of rare bone-forming disease · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “J&J’s Imaavy wins label expansion; Two approvals in Japan.” Browse more stories.